Evidence map›Paper›PMID 34681053›Full record

ArticleBiology2021

R-Score: A New Parameter to Assess the Quality of Variants' Calls Assessed by NGS Using Liquid Biopsies.

Roberto Serna-Blasco, Estela Sánchez-Herrero, María Berrocal Renedo, Silvia Calabuig-Fariñas, Miguel Ángel Molina-Vila, Mariano Provencio, Atocha Romero

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Roberto Serna-BlascoLiquid Biopsy Laboratory, University Hospital Puerta de Hierro, 28222 Madrid, Spain.
Estela Sánchez-HerreroLiquid Biopsy Laboratory, University Hospital Puerta de Hierro, 28222 Madrid, Spain.
María Berrocal RenedoLiquid Biopsy Laboratory, University Hospital Puerta de Hierro, 28222 Madrid, Spain.
Silvia Calabuig-FariñasCIBERONC, Liquid Biopsy WM, 28029 Madrid, Spain.ORCID 0000-0001-7749-174X
Miguel Ángel Molina-VilaLaboratory of Oncology/Pangaea Oncology, Quirón-Dexeus University Hospital, 08028 Barcelona, Spain.ORCID 0000-0001-8866-9881
Mariano ProvencioMedical Oncology, University Hospital Puerta de Hierro, 28222 Madrid, Spain.ORCID 0000-0001-6315-7919
Atocha RomeroLiquid Biopsy Laboratory, University Hospital Puerta de Hierro, 28222 Madrid, Spain.

Funding

Consejería de Educación e Investigación IND2019/BMD-17258Consejería de Educación e Investigación PEJD-2018-PRE/BMD-8640Horizon 2020 875160Instituto de Salud Carlos III PI16/18018
6 · The paper itself

Abstract

Next-generation sequencing (NGS) has enabled a deeper knowledge of the molecular landscape in non-small cell lung cancer (NSCLC), identifying a growing number of targetable molecular alterations in key genes. However, NGS profiling of liquid biopsies risk for false positive and false negative calls and parameters assessing the quality of NGS calls remains lacking. In this study, we have evaluated the positive percent agreement (PPA) between NGS and digital PCR calls when assessing

Indexed as

ctDNAfilteringliquid biopsyNGSVAFvariant calling

Identifiers

PMID34681053
PMCPMC8533561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.